Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 699-709

  Nguyen, Tri Hung ^a   Havari, Evis ^a   McLaren, Rajashree ^a   Zhang, Mindy ^a   Jiang, Yide ^a   Madden, Stephen L ^a   Roberts, Bruce ^a   Kaplan, Johanne ^a   Shankara, Srinivas ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Alemtuzumab; Apoptosis; CD52; Cell signaling; Cross linking

Indexed keywords

ALEMTUZUMAB; CALCIUM ION; CASPASE; CD32 ANTIGEN; CD52 ANTIGEN; FC RECEPTOR IIB; PHOSPHOTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CAPPING PHENOMENON; CELL STRESS; CELL SURFACE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CROSS LINKING; DRUG BINDING; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CALCIUM; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SPACE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, IGG; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859055244     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.623253     Document Type: Article

References (42)

1. Xia MQ, Tone M, Packman L, et al. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 1991;21:1677-1684.
2. Xia MQ, Hale G, Lifely MR, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293(Pt 3):633-640.
3. Hale G, Rye PD, Warford A, et al. Th e glycosylphosphatidylinositolanchored lymphocyte antigen CDw52 is associated with theepididymal maturation of human spermatozoa. J Reprod Immunol 1993;23:189-205.
4. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-191.
5. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255:231-238.
6. Jones JL, Coles AJ. Campath-1H treatment of multiple sclerosis. Neurodegener Dis 2008;5:27-31.
7. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000;26:69-76.
8. Watanabe T, Masuyama J, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+regulatory T cells. Clin Immunol 2006;120 :247-259.
9. Bloom DD, Chang Z, Fechner JH, et al. CD4+CD25+FOXP3+regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008;8:793-802.
10. Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, et al. CD52 over-expression aff ects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma 2007;48:2424-2436.
11. Zent CS, Secreto CR, LaPlant BR, et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk earlyintermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008;32:1849-1856.
12. Golay J, Manganini M, Rambaldi A, et al. Eff ect of alemtuzumab on neoplastic B cells. Haematologica 2004;89:1476-1483.
13. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128:260-270.
14. Siders WM, Shields J, Garron C, et al. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma 2010;51:1293-1304.
15. Rowan W, Tite J, Topley P, et al. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-defi cient cells. Immunology 1998;95:427-436.
16. Nuckel H, Frey UH, Roth A, et al. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 2005;514:217-224.
17. Mone AP, Cheney C, Banks AL, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006;20:272-279.
18. Stanglmaier M, Reis S, Hallek M. Rituximab anDalemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004;83:634-645.
19. Kim KM, Yoshimura T, Watanabe H, et al. Growth regulation of a human mature B cell line, B104, by anti-IgM and anti-IgD antibodies. J Immunol 1991;146:819-825.
20. Siebenlist U, Hennighausen L, Battey J, et al. Chromatin structure and protein binding in the putative regulatory region of the c-myc gene in Burkitt lymphoma. Cell 1984;37:381-391.
21. Nacheva E, Fischer P, Karpas A, et al. Complex translocation t(8;12;14) in a cell line derived from a child with nonendemic Burkitt-type acute lymphoblastic leukemia. Cancer Genet Cytogenet 1987;28:145-153.
22. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4354.
23. Nguyen TH, Liu J, Lombroso PJ. Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. J Biol Chem 2002;277:24274-24279.
24. Wu Z, Irizarry RA. Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J Comput Biol 2005;12:882-893.
25. Wu Z, Irizarry RA, Gentleman R, et al. A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. J Am Statist Assoc 2004;99:909-917.
26. Tan Y, Rouse J, Zhang A, et al. FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J 1996;15:4629-4642.
27. Gamberale R, Geff ner JR, Sanjurjo J, et al. Expression of Fcgamma receptors type II (FcgammaRII) in chronic lymphocytic leukemia B cells. Blood 2003;102:2698-2699.
28. Camilleri-Broet S, Cassard L, Broet P, et al. FcgammaRIIB is diff erentially expressed during B cell maturation and in B-cell lymphomas. Br J Haematol 2004;124:55-62.
29. Gousset K, Wolkers WF, Tsvetkova NM, et al. Evidence for a physiological role for membrane rafts in human platelets. J Cell Physiol 2002;190:117-128.
30. Omidvar N, Wang EC, Brennan P, et al. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. J Immunol 2006;176:2915-2923.
31. Morgan BP, van den Berg CW, Davies EV, et al. Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase. Eur J Immunol 1993;23:2841-2850.
32. Harder T, Scheiff ele P, Verkade P, et al. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol 1998;141:929-942.
33. Gupta N, Wollscheid B, Watts JD, et al. Quantitative proteomic analysis of B cell lipid rafts reveals that ezrin regulates antigen receptormediated lipid raft dynamics. Nat Immunol 2006;7:625-633.
34. Fang LW, Tai TS, Yu WN, et al. Phosphatidylinositide 3-kinase priming couples c-FLIP to T cell activation. J Biol Chem 2004;279:13-18.
35. Freedman BD, Liu QH, Somersan S, et al. Receptor avidity and costimulation specify the intracellular Ca2+signaling pattern in CD4(+)CD8(+) thymocytes. J Exp Med 1999;190:943-952.
36. Engelke M, Engels N, Dittmann K, et al. Ca(2+) signaling in antigen receptor-activated B lymphocytes. Immunol Rev 2007;218:235-246.
37. Vig M, Kinet JP. Calcium signaling in immune cells. Nat Immunol 2009;10:21-27.
38. Bishop GA, Haxhinasto SA, Stunz LL, et al. Antigen-specifi c B-lymphocyte activation. Crit Rev Immunol 2003;23:149-197.
39. Osterborg A, Karlsson C, Lundin J, et al. Strategies in the management of alemtuzumab-related side eff ects. Semin Oncol 2006;33:S29-S35.
40. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119(Pt 1):225-237.
41. Wing MG, Moreau T, Greenwood J, et al. Mechanism of fi rst-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996;98:2819-2826.
42. Smolewski P, Duechler M, Linke A, et al. Additive cytotoxic eff ect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leuk Res 2006;30:1521-9.